Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Luminex Corporation Awarded $11 Million Contract by Defense Threat Reduction Agency (DTRA)

Published: Thursday, August 16, 2012
Last Updated: Thursday, August 16, 2012
Bookmark and Share
Department of Defense award accelerates development of Luminex bio-threat detection technology program.

Luminex Corporation announced it has been awarded a contract worth up to $11.6 million over three and a half years. The contract will fund development of a prototype instrument that is highly portable, field-deployable diagnostic tool capable of rapid detection of biothreat agents and patient response biomarkers indicative of systemic disease. This hand-held system will detect both protein and nucleic acid targets to aid diagnosis of Systemic Inflammatory Response Syndrome (SIRS), a consequence of blood infection in conventional combat, biowarfare and combat operations in developing and resource-limited areas.

Infection and disease caused by biowarfare agents carry the very real threat of catastrophic illness and death of military and civilian personnel.  The pathophysiology of candidate biowarfare microbes is varied and may involve multiple organ systems, but there are some common features associated with bloodstream infection that permit the development of a sensitive diagnostic test that not only identifies biowarfare pathogens but also can be use outside of an executed bioagent attack.

"Rapid response and informed decisions on therapeutic options are critical in managing biothreat agent exposure," said Amy Altman, Ph.D., vice president Luminex Biodefense. "The flexibility and scalability of our multiplexing technology allow for the measurement of RNA, DNA and proteins with the same system, aiding rapid and accurate diagnosis of these severe conditions.  Development of a field deployable device using our technology has the potential to provide significant advancement in biothreat detection."

"Luminex is highly committed to success in the area of biodefense. We are pleased that DTRA recognizes the potential contribution our technology can make in the detection of biothreat agents," said Patrick J. Balthrop, president and CEO of Luminex.  "We look forward to collaborating on this important initiative by developing innovative solutions for combating biothreat agents and protecting the safety of people everywhere."

The contract awarded to Luminex supports The Chemical and Biological Defense Initiative Fund (CMB-DIAGB2) U.S. Department of Defense's Defense Threat Reduction Agency (DTRA).  Solicitation was issued for full and open competition and 56 proposals were received.  Established in 1998, the Defense Threat Reduction Agency (DTRA) provides the Department of Defense's core intellectual, technical and operational support expertise for countering threats posed by weapons of mass destruction (chemical, biological, radiological, and nuclear) and high-yield explosives.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Luminex Zika Test Granted FDA Emergency Use Authorization
The test is designed to detect zika virus RNA in potentially infected patients using their blood serum, plasma, or urine.
Tuesday, August 09, 2016
Luminex Corporation Receives FDA Clearance
Company has received FDA clearance for new molecular test for identification and differentiation of influenza A/B and respiratory syncytial virus.
Thursday, August 04, 2016
Luminex Receives FDA Clearance for Aries M1 System
Company has received FDA clearance and CE-IVD marking for a new in vitro diagnostic system, the ARIES® M1 System.
Thursday, July 07, 2016
Luminex Completes Acquisition of Nanosphere
The acquisition provides Luminex with Nanosphere's high-plex, low-throughput system to complement its existing molecular platforms.
Friday, July 01, 2016
Luminex Receives CE-IVD Mark
Company has announced that it has received CE-IVD mark for ARIES® Flu A/B & RSV Assay.
Thursday, June 02, 2016
Luminex to Acquire Nanosphere
Nanosphere to be acquired for $1.35 per share in an all cash transaction valued at approximately $58 million.
Monday, May 16, 2016
Luminex SYNCT Software Receives FDA Clearance, CE Mark
Company has announced that its SYNCT™ Software has received both U.S. FDA clearance and CE Marking for use with its ARIES® System and NxTAG® assays on the MAGPIX® System.
Friday, April 15, 2016
Luminex Receives CE-IVD Mark for ARIES System
The ARIES® System and ARIES®HSV 1&2 Assay previously received FDA clearance in October 2015 and were subsequently launched in the U.S. market.
Tuesday, March 22, 2016
Luminex, University of Sao Paulo Collaborate
Luminex Corporation has announced it is collaborating with the Laboratory of Molecular Evolution & Bioinformatics, Biomedical Sciences Institute, University of São Paulo, Brazil to validate a multi-analyte Zika virus assay developed by Luminex partner,GenArraytion, Inc.
Monday, February 29, 2016
Luminex Corporation Announces Collaboration with University of Sao Paulo
Company has announced collaboration to validate a multi analyte zika virus detection panel for detect multiple disease agent.
Friday, February 26, 2016
Luminex Corporation Receives Medical Device License
Company has announced that it has received medical device licenses from Health Canada's Therapeutic Products Directorate for ARIES System and ARIES HSV 1&2 Assay.
Tuesday, February 23, 2016
Luminex and Bio-Techne Extend and Expand Partnership
Company expands global distribution of award-winning multiplexing instrumentation.
Friday, October 23, 2015
Luminex Receives FDA Clearance
Company has received clearance for ARIES® System and ARIES® HSV 1&2 Assay.
Thursday, October 08, 2015
Luminex Receives FDA and European Clearance for xTAG® CYP2C19 Kit
New cytochrome P450 2C19 assay helps physicians optimize individual patient care.
Tuesday, September 24, 2013
Luminex Corporation Reports Second Quarter 2013 Results
Achieves milestone selling 10,000th multiplexing analyzer.
Tuesday, July 30, 2013
Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
New Diagnostic Tool for Familial Mediterranean Fever
A new tool developed by researchers at VIB and Ghent University could improve the process of diagnosing Familial Mediterranean Fever.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Molecular Signature for Aggressive Brain Tumor Uncovered
Researchers have identified genetic mutations in a highly agressive brain cancer that distinguishes the agressive, from the benign forms of the cancer.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
GFC Diagnostics Wins Longitude Prize Discovery Award
The global award was won for the development of a cheap, quick and simple MRSA Test.
Understanding Circulating Tumour Cells
Research team develops new tool to track traveling cancer cells in the bloodstream.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!